DSMB Recommends Continuation Of RedHill Biopharma's Phase 2/3 Covid Study Of Opaganib

RedHill Biopharma Ltd. (RDHL) said the mid/late stage study of its Covid-19 drug candidate, Opaganib passed fourth review by an independent Data Safety Monitoring Board (DSMB).

Following the analysis of safety data from the first 255 patients of total 380, treated with Opaganib for 14 days, the company received unanimous recommendation from DSMB to continue the Phase 2/3 study of orally-administered opaganib in severe Covid-19 pneumonia.

Redhill said a 464-patient global Phase 2/3 study of Opaganib in Covid-19 is going on.

"Adding together the positive Phase 2 data, the successful DSMB futility reviews and the outcomes from compassionate use of opaganib, we look forward with optimism to the reporting of top-line data from the Phase 2/3 study, which will provide the clearest indication to date of opaganib's promise in treating COVID-19," Mark L. Levitt, Medical Director at RedHill, said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention... Generac Power Systems is recalling 325,735 units of Generac and DR 6500 Watt and 8000 Watt portable generators for potential risk of finger amputation and crushing hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include 4,575 units sold in Canada. Omaha, Nebraska- based Greater Omaha Packing is recalling around 295,236 pounds of raw beef products citing the possible presence of E. coli O157:H7, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The raw beef products intended for non-intact use were produced on July 13.
Follow RTT